1
|
McGale JP, Chen DL, Trebeschi S, Farwell MD, Wu AM, Cutler CS, Schwartz LH, Dercle L. Artificial intelligence in immunotherapy PET/SPECT imaging. Eur Radiol 2024:10.1007/s00330-024-10637-3. [PMID: 38355986 DOI: 10.1007/s00330-024-10637-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2023] [Revised: 12/12/2023] [Accepted: 01/15/2024] [Indexed: 02/16/2024]
Abstract
OBJECTIVE Immunotherapy has dramatically altered the therapeutic landscape for oncology, but more research is needed to identify patients who are likely to achieve durable clinical benefit and those who may develop unacceptable side effects. We investigated the role of artificial intelligence in PET/SPECT-guided approaches for immunotherapy-treated patients. METHODS We performed a scoping review of MEDLINE, CENTRAL, and Embase databases using key terms related to immunotherapy, PET/SPECT imaging, and AI/radiomics through October 12, 2022. RESULTS Of the 217 studies identified in our literature search, 24 relevant articles were selected. The median (interquartile range) sample size of included patient cohorts was 63 (157). Primary tumors of interest were lung (n = 14/24, 58.3%), lymphoma (n = 4/24, 16.7%), or melanoma (n = 4/24, 16.7%). A total of 28 treatment regimens were employed, including anti-PD-(L)1 (n = 13/28, 46.4%) and anti-CTLA-4 (n = 4/28, 14.3%) monoclonal antibodies. Predictive models were built from imaging features using univariate radiomics (n = 7/24, 29.2%), radiomics (n = 12/24, 50.0%), or deep learning (n = 5/24, 20.8%) and were most often used to prognosticate (n = 6/24, 25.0%) or describe tumor phenotype (n = 5/24, 20.8%). Eighteen studies (75.0%) performed AI model validation. CONCLUSION Preliminary results suggest broad potential for the application of AI-guided immunotherapy management after further validation of models on large, prospective, multicenter cohorts. CLINICAL RELEVANCE STATEMENT This scoping review describes how artificial intelligence models are built to make predictions based on medical imaging and explores their application specifically in the PET and SPECT examination of immunotherapy-treated cancers. KEY POINTS • Immunotherapy has drastically altered the cancer treatment landscape but is known to precipitate response patterns that are not accurately accounted for by traditional imaging methods. • There is an unmet need for better tools to not only facilitate in-treatment evaluation but also to predict, a priori, which patients are likely to achieve a good response with a certain treatment as well as those who are likely to develop side effects. • Artificial intelligence applied to PET/SPECT imaging of immunotherapy-treated patients is mainly used to make predictions about prognosis or tumor phenotype and is built from baseline, pre-treatment images. Further testing is required before a true transition to clinical application can be realized.
Collapse
Affiliation(s)
- Jeremy P McGale
- Department of Radiology, New York-Presbyterian Hospital, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
| | - Delphine L Chen
- Department of Molecular Imaging and Therapy, Fred Hutchinson Cancer Center, Seattle, WA, USA
- Department of Radiology, University of Washington, Seattle, WA, USA
| | - Stefano Trebeschi
- Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands
- GROW School of Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands
| | - Michael D Farwell
- Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Anna M Wu
- Department of Immunology and Theranostics, Beckman Research Institute of City of Hope, Duarte, CA, USA
| | - Cathy S Cutler
- Collider Accelerator Department, Brookhaven National Laboratory, Upton, NY, USA
| | - Lawrence H Schwartz
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Laurent Dercle
- Department of Radiology, New York-Presbyterian Hospital, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
| |
Collapse
|
2
|
Phipps MD, Cingoranelli S, Bhupathiraju NVSDK, Younes A, Cao M, Sanders VA, Neary MC, Daveny MH, Cutler CS, Lopez GE, Saini S, Parker CC, Fernandez SR, Lewis JS, Lapi SE, Francesconi LC, Deri MA. Sc-HOPO: A Potential Construct for Use in Radioscandium-Based Radiopharmaceuticals. Inorg Chem 2023; 62:20567-20581. [PMID: 36724083 PMCID: PMC10390652 DOI: 10.1021/acs.inorgchem.2c03931] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Three isotopes of scandium─43Sc, 44Sc, and 47Sc─have attracted increasing attention as potential candidates for use in imaging and therapy, respectively, as well as for possible theranostic use as an elementally matched pair. Here, we present the octadentate chelator 3,4,3-(LI-1,2-HOPO) (or HOPO), an effective chelator for hard cations, as a potential ligand for use in radioscandium constructs with simple radiolabeling under mild conditions. HOPO forms a 1:1 Sc-HOPO complex that was fully characterized, both experimentally and theoretically. [47Sc]Sc-HOPO exhibited good stability in chemical and biological challenges over 7 days. In healthy mice, [43,47Sc]Sc-HOPO cleared the body rapidly with no signs of demetalation. HOPO is a strong candidate for use in radioscandium-based radiopharmaceuticals.
Collapse
Affiliation(s)
- Michael D Phipps
- Ph.D. Program in Chemistry, The Graduate Center of the City University of New York, New York, NY 10016
- Department of Chemistry, City University of New York Hunter College, 695 Park Avenue, New York, New York 10065
- Department of Chemistry, Lehman College of the City University of New York, Bronx, NY 10468
- Medical Isotope Research & Production Laboratory, Collider-Accelerator Division, Brookhaven National Laboratory, Upton, NY, 11973, USA
| | - Shelbie Cingoranelli
- Department of Radiology, University of Alabama at Birmingham, Birmingham, AL 35294
| | | | - Ali Younes
- Department of Chemistry, City University of New York Hunter College, 695 Park Avenue, New York, New York 10065
| | - Minhua Cao
- Department of Chemistry, City University of New York Hunter College, 695 Park Avenue, New York, New York 10065
| | - Vanessa A. Sanders
- Medical Isotope Research & Production Laboratory, Collider-Accelerator Division, Brookhaven National Laboratory, Upton, NY, 11973, USA
| | - Michelle C. Neary
- Department of Chemistry, City University of New York Hunter College, 695 Park Avenue, New York, New York 10065
| | - Matthew H. Daveny
- Department of Chemistry, City University of New York Hunter College, 695 Park Avenue, New York, New York 10065
| | - Cathy S. Cutler
- Medical Isotope Research & Production Laboratory, Collider-Accelerator Division, Brookhaven National Laboratory, Upton, NY, 11973, USA
| | - Gustavo E. Lopez
- Ph.D. Program in Chemistry, The Graduate Center of the City University of New York, New York, NY 10016
- Department of Chemistry, Lehman College of the City University of New York, Bronx, NY 10468
| | - Shefali Saini
- Department of Radiology, University of Alabama at Birmingham, Birmingham, AL 35294
| | - Candace C. Parker
- Department of Radiology, University of Alabama at Birmingham, Birmingham, AL 35294
| | - Solana R. Fernandez
- Department of Radiology, University of Alabama at Birmingham, Birmingham, AL 35294
| | - Jason S. Lewis
- Program in Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, NY 10065
| | - Suzanne E. Lapi
- Department of Radiology, University of Alabama at Birmingham, Birmingham, AL 35294
| | - Lynn C. Francesconi
- Ph.D. Program in Chemistry, The Graduate Center of the City University of New York, New York, NY 10016
- Department of Chemistry, City University of New York Hunter College, 695 Park Avenue, New York, New York 10065
| | - Melissa A. Deri
- Ph.D. Program in Chemistry, The Graduate Center of the City University of New York, New York, NY 10016
- Department of Chemistry, Lehman College of the City University of New York, Bronx, NY 10468
| |
Collapse
|
3
|
Gajecki L, Marino CM, Cutler CS, Sanders VA. Evaluation of hydroxamate-based resins towards a more clinically viable 44Ti/ 44Sc radionuclide generator. Appl Radiat Isot 2023; 192:110588. [PMID: 36470155 DOI: 10.1016/j.apradiso.2022.110588] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2022] [Revised: 11/21/2022] [Accepted: 11/24/2022] [Indexed: 11/30/2022]
Abstract
Several hydroxamate-based resins were synthesized and tested for use in 44Ti/44Sc generator systems in small scale experiments (740 kBq 44Ti). The most promising resin was tested further in larger scale generator studies (37 MBq). This resin displayed impressive retention of 44Ti over several elutions, and high quantities of 44Sc were obtained in small volumes of dilute HCl eluents. Initial radiolabeling experiments were conducted and demonstrated the possibility of direct radiolabeling of the generator produced 44Sc with DOTA.
Collapse
Affiliation(s)
- Leah Gajecki
- Collider Accelerator Department, Brookhaven National Laboratory, Upton, NY, 11973, USA.
| | - Celine M Marino
- Collider Accelerator Department, Brookhaven National Laboratory, Upton, NY, 11973, USA; Chemistry Department, Stony Brook University, Stony Brook, NY, 11794, USA
| | - Cathy S Cutler
- Collider Accelerator Department, Brookhaven National Laboratory, Upton, NY, 11973, USA
| | - Vanessa A Sanders
- Collider Accelerator Department, Brookhaven National Laboratory, Upton, NY, 11973, USA
| |
Collapse
|
4
|
Younes A, Fitzsimmons J, Ali JS, Groveman S, Cutler CS, Medvedev D. Inorganic resins enable the increased purification efficiency of 82Sr from rubidium targets for use in PET imaging isotope production. J Radioanal Nucl Chem 2022. [DOI: 10.1007/s10967-022-08498-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
5
|
Ma L, Grant C, Gallazzi F, Watkinson LD, Carmack TL, Embree MF, Smith CJ, Medvedev D, Cutler CS, Li Y, Wilbur DS, Hennkens HM, Jurisson SS. Development and biodistribution studies of 77As-labeled trithiol RM2 bioconjugates for prostate cancer: Comparison of [77As]As-trithiol-Ser-Ser-RM2 vs. [77As]As-trithiol-Glu-Ser-RM2. Nucl Med Biol 2022; 108-109:61-69. [DOI: 10.1016/j.nucmedbio.2022.03.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2021] [Revised: 02/26/2022] [Accepted: 03/11/2022] [Indexed: 02/07/2023]
|
6
|
Charles A, Khosrashahi FN, Ma L, Munindradasa C, Hoerres R, Lydon JD, Kelley SP, Guthrie J, Rotsch D, Medvedev D, Cutler CS, Li Y, Wilbur DS, Hennkens HM, Jurisson SS. Evaluation of 186WS 2 target material for production of high specific activity 186Re via proton irradiation: separation, radiolabeling and recovery/recycling. RADIOCHIM ACTA 2022. [DOI: 10.1515/ract-2021-1138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Abstract
Enriched tungsten disulfide (186WS2) was evaluated at increasing proton beam currents (20–50 μA) and times (up to 4 h) on a GE PETtrace cyclotron for production of high specific activity (HSA) 186Re. The HSA 186Re was separated from the irradiated target as [186Re][ReO4]– by a liquid–liquid extraction method and radiolabeled with a new N2S2 ligand (222-MAMA-N-ethylpropionate). The enriched 186W was recovered from the extraction process, analyzed for purity and enrichment, and converted back to the disulfide (186WS2). The results demonstrate that the 186WS2 is an easily pressed target material that can withstand relatively high currents and can be readily recovered and recycled. The 186Re produced was isolated in high specific activity and readily formed the radiotracers [186Re][ReO(222-MAMA-N-ethylpropionate)] and [186Re][Re(CO)3(OH2)3] +.
Collapse
Affiliation(s)
- Anster Charles
- Department of Chemistry , University of Missouri , Columbia , MO , USA
| | | | - Li Ma
- Department of Chemistry , University of Missouri , Columbia , MO , USA
| | | | - Rebecca Hoerres
- Department of Chemistry , University of Missouri , Columbia , MO , USA
| | - John D. Lydon
- University of Missouri Research Reactor Center (MURR) , Columbia , MO , USA
| | - Steven P. Kelley
- Department of Chemistry , University of Missouri , Columbia , MO , USA
| | - James Guthrie
- University of Missouri Research Reactor Center (MURR) , Columbia , MO , USA
| | | | - Dmitri Medvedev
- Collider Accelerator Department , Brookhaven National Laboratory , Upton , NY , USA
| | - Cathy S. Cutler
- Collider Accelerator Department , Brookhaven National Laboratory , Upton , NY , USA
| | - Yawen Li
- Department of Radiation Oncology , University of Washington , Seattle , WA , USA
| | - D. Scott Wilbur
- Department of Radiation Oncology , University of Washington , Seattle , WA , USA
| | - Heather M. Hennkens
- Department of Chemistry , University of Missouri , Columbia , MO , USA
- University of Missouri Research Reactor Center (MURR) , Columbia , MO , USA
| | | |
Collapse
|
7
|
Mou L, Martini P, Pupillo G, Cieszykowska I, Cutler CS, Mikołajczak R. 67Cu Production Capabilities: A Mini Review. Molecules 2022; 27:molecules27051501. [PMID: 35268600 PMCID: PMC8912090 DOI: 10.3390/molecules27051501] [Citation(s) in RCA: 18] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/31/2022] [Revised: 02/15/2022] [Accepted: 02/18/2022] [Indexed: 01/09/2023]
Abstract
Is the 67Cu production worldwide feasible for expanding preclinical and clinical studies? How can we face the ingrowing demands of this emerging and promising theranostic radionuclide for personalized therapies? This review looks at the different production routes, including the accelerator- and reactor-based ones, providing a comprehensive overview of the actual 67Cu supply, with brief insight into its use in non-clinical and clinical studies. In addition to the most often explored nuclear reactions, this work focuses on the 67Cu separation and purification techniques, as well as the target material recovery procedures that are mandatory for the economic sustainability of the production cycle. The quality aspects, such as radiochemical, chemical, and radionuclidic purity, with particular attention to the coproduction of the counterpart 64Cu, are also taken into account, with detailed comparisons among the different production routes. Future possibilities related to new infrastructures are included in this work, as well as new developments on the radiopharmaceuticals aspects.
Collapse
Affiliation(s)
- Liliana Mou
- Legnaro National Laboratories, National Institute for Nuclear Physics, Legnaro, 35020 Padova, Italy; (L.M.); (G.P.)
| | - Petra Martini
- Department of Environmental and Prevention Sciences, University of Ferrara, 44121 Ferrara, Italy; or
| | - Gaia Pupillo
- Legnaro National Laboratories, National Institute for Nuclear Physics, Legnaro, 35020 Padova, Italy; (L.M.); (G.P.)
| | - Izabela Cieszykowska
- National Centre for Nuclear Research, Radioisotope Centre POLATOM, 05-400 Otwock, Poland;
| | - Cathy S. Cutler
- Brookhaven National Laboratory, Collider Accelerator Department, Upton, NY 11973, USA;
| | - Renata Mikołajczak
- National Centre for Nuclear Research, Radioisotope Centre POLATOM, 05-400 Otwock, Poland;
- Correspondence:
| |
Collapse
|
8
|
Radchenko V, Morgenstern A, Jalilian A, Ramogida C, Cutler CS, Duchemin C, Hoehr C, Haddad F, Bruchertseifer F, Gausemel H, Yang H, Osso JA, Washiyama K, Czerwinski K, Leufgen K, Pruszynski M, Valzdorf O, Causey P, Schaffer P, Perron R, Samsonov M, Wilbur DS, Stora T, Li Y. Production and supply of alpha particles emitting radionuclides for Targeted Alpha Therapy (TAT). J Nucl Med 2021; 62:1495-1503. [PMID: 34301779 DOI: 10.2967/jnumed.120.261016] [Citation(s) in RCA: 40] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2021] [Accepted: 06/29/2021] [Indexed: 11/16/2022] Open
Abstract
Encouraging results of Targeted Alpha Therapy (TAT) have created significant attention from academia and industry. However, the limited availability of suitable radionuclides has hampered widespread translation and application. In the present review, we discuss the most promising candidates for clinical application and the state of the art of their production and supply. Along with forthcoming another two reviews on chelation and clinical application of alpha-emitting radionuclides, JNM will provide a comprehensive assessment of the field.
Collapse
|
9
|
Carter LM, Kesner AL, Pratt EC, Sanders VA, Massicano AVF, Cutler CS, Lapi SE, Lewis JS. The Impact of Positron Range on PET Resolution, Evaluated with Phantoms and PHITS Monte Carlo Simulations for Conventional and Non-conventional Radionuclides. Mol Imaging Biol 2021; 22:73-84. [PMID: 31001765 DOI: 10.1007/s11307-019-01337-2] [Citation(s) in RCA: 36] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
PURPOSE The increasing interest and availability of non-standard positron-emitting radionuclides has heightened the relevance of radionuclide choice in the development and optimization of new positron emission tomography (PET) imaging procedures, both in preclinical research and clinical practice. Differences in achievable resolution arising from positron range can largely influence application suitability of each radionuclide, especially in small-ring preclinical PET where system blurring factors due to annihilation photon acollinearity and detector geometry are less significant. Some resolution degradation can be mitigated with appropriate range corrections implemented during image reconstruction, the quality of which is contingent on an accurate characterization of positron range. PROCEDURES To address this need, we have characterized the positron range of several standard and non-standard PET radionuclides (As-72, F-18, Ga-68, Mn-52, Y-86, and Zr-89) through imaging of small-animal quality control phantoms on a benchmark preclinical PET scanner. Further, the Particle and Heavy Ion Transport code System (PHITS v3.02) code was utilized for Monte Carlo modeling of positron range-dependent blurring effects. RESULTS Positron range kernels for each radionuclide were derived from simulation of point sources in ICRP reference tissues. PET resolution and quantitative accuracy afforded by various radionuclides in practicable imaging scenarios were characterized using a convolution-based method based on positron annihilation distributions obtained from PHITS. Our imaging and simulation results demonstrate the degradation of small animal PET resolution, and quantitative accuracy correlates with increasing positron energy; however, for a specific "benchmark" preclinical PET scanner and reconstruction workflow, these differences were observed to be minimal given radionuclides with average positron energies below ~ 400 keV. CONCLUSION Our measurements and simulations of the influence of positron range on PET resolution compare well with previous efforts documented in the literature and provide new data for several radionuclides in increasing clinical and preclinical use. The results will support current and future improvements in methods for positron range corrections in PET imaging.
Collapse
Affiliation(s)
- L M Carter
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Adam Leon Kesner
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
| | - E C Pratt
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Department of Pharmacology, Weill Cornell Medical College, New York, NY, USA
| | - V A Sanders
- Collider-Accelerator Department, Brookhaven National Laboratory, Upton, NY, USA
| | - A V F Massicano
- Department of Radiology, University of Alabama at Birmingham, Birmingham, AL, USA
| | - C S Cutler
- Collider-Accelerator Department, Brookhaven National Laboratory, Upton, NY, USA
| | - S E Lapi
- Department of Radiology, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Jason S Lewis
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Department of Pharmacology, Weill Cornell Medical College, New York, NY, USA.
- Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Department of Radiology, Weill Cornell Medical College, New York, NY, USA.
- Radiochemistry and Molecular Imaging Probes Core, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
| |
Collapse
|
10
|
Hatcher-Lamarre JL, Sanders VA, Rahman M, Cutler CS, Francesconi LC. Alpha emitting nuclides for targeted therapy. Nucl Med Biol 2021; 92:228-240. [PMID: 33558017 PMCID: PMC8363053 DOI: 10.1016/j.nucmedbio.2020.08.004] [Citation(s) in RCA: 25] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2020] [Revised: 08/25/2020] [Accepted: 08/26/2020] [Indexed: 02/07/2023]
Abstract
Targeted alpha therapy (TAT) is an area of research with rapidly increasing importance as the emitted alpha particle has a significant effect on inducing cytotoxic effects on tumor cells while mitigating dose to normal tissues. Two significant isotopes of interest within the area of TAT are thorium-227 and actinium-225 due to their nuclear characteristics. Both isotopes have physical half-lives suitable for coordination with larger biomolecules, and additionally actinium-225 has potential to serve as an in vivo generator. In this review, the authors will discuss the production, purification, labeling reactions, and biological studies of actinium-225 and thorium-227 complexes and clinical studies.
Collapse
Affiliation(s)
| | - Vanessa A Sanders
- Collider Accelerator Department, Brookhaven National Laboratory, USA
| | - Mohammed Rahman
- Chemistry Department, Hunter College of the City University of New York, USA
| | - Cathy S Cutler
- Collider Accelerator Department, Brookhaven National Laboratory, USA
| | - Lynn C Francesconi
- Chemistry Department, Hunter College of the City University of New York, USA; Chemistry Department, Graduate Center of the City University of New York, USA.
| |
Collapse
|
11
|
Aime S, Amirshaghaghi A, Angel PM, Ardenkjaer-Larsen JH, Atreya R, Awe S, Badea CT, Beekman FJ, Biade S, Borden MA, Brunsing RL, Chandrasekharan P, Chang JB, Chen F, Chen JW, Chen X, Cheng Z, Cheng Z, Cherin E, Clinthorne NH, Cohen J, Colson C, Conolly S, Contag CH, Cutler CS, Dayton PA, Devoogdt N, Dina O, Drake RR, Dubsky S, Ducongé F, Fellows BD, Foster FS, Francis KP, Fung BK, Gambhir SS, Gao R, Giovenzana GB, Goodwill P, Goorden MC, Gorpas D, Grimm J, Groll AN, Hargus S, Harmsen S, He S, Hensley D, Hutton BF, Huynh Q, Iagaru A, Josephson L, Jurisson SS, Keselman P, Kircher MF, Kokate T, Konkle J, Korsen JA, Krasniqi A, Laniyonu A, Levin CS, Lewis MR, Lewis JS, Liu G, Liu Y, Looger LL, Lu K, Lu Y, Lucignani G, Lyons SK, Maina T, Martelli C, Matheson AM, Mempel TR, Meng LJ, Moradi F, Nagle VL, Neurath MF, Nicolson F, Nie L, Ntziachristos V, Orendorff R, Ottobrini L, Ouyang Y, Paez Segala MG, Parraga G, Perez-Liva M, Pratt EC, Rao J, Rath T, Rodriguez E, Rosenthal EL, Ross BD, Saayujya C, Saritas EU, Scott DA, Sheth VR, Slagle C, Tamura R, Tavitian B, Tay ZW, Terreno E, Thakur M, Thompson C, Tian J, Travagin F, Tsourkas A, Tully KM, Usmani SM, VanBrocklin HF, van Keulen S, van Zijl PC, Walmer RW, Wang C, Wang J, Wang LV, Xavier C, Yao J, Yu EY, Zheng X, Zheng B, Zhou XY. Contributors. Mol Imaging 2021. [DOI: 10.1016/b978-0-12-816386-3.01002-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
12
|
Lewis MR, Cutler CS, Jurisson SS. Targeted Antibodies and Peptides. Mol Imaging 2021. [DOI: 10.1016/b978-0-12-816386-3.00022-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
13
|
Cutler CS, Bailey E, Kumar V, Schwarz SW, Bom HS, Hatazawa J, Paez D, Orellana P, Louw L, Mut F, Kato H, Chiti A, Frangos S, Fahey F, Dillehay G, Oh SJ, Lee DS, Lee ST, Nunez-Miller R, Bandhopadhyaya G, Pradhan PK, Scott AM. Global Issues of Radiopharmaceutical Access and Availability: A Nuclear Medicine Global Initiative Project. J Nucl Med 2020; 62:422-430. [PMID: 32646881 DOI: 10.2967/jnumed.120.247197] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2020] [Accepted: 06/15/2020] [Indexed: 12/21/2022] Open
Abstract
The Nuclear Medicine Global Initiative was formed in 2012 by 13 international organizations to promote human health by advancing the field of nuclear medicine and molecular imaging by supporting the practice and application of nuclear medicine. The first project focused on standardization of administered activities in pediatric nuclear medicine and resulted in 2 articles. For its second project the Nuclear Medicine Global Initiative chose to explore issues impacting on access and availability of radiopharmaceuticals around the world. Methods: Information was obtained by survey responses from 35 countries on available radioisotopes, radiopharmaceuticals, and kits for diagnostic and therapeutic use. Issues impacting on access and availability of radiopharmaceuticals in individual countries were also identified. Results: Detailed information on radiopharmaceuticals used in each country, and sources of supply, was evaluated. Responses highlighted problems in access, particularly due to the reliance on a sole provider, regulatory issues, and reimbursement, as well as issues of facilities and workforce, particularly in low- and middle-income countries. Conclusion: Strategies to address access and availability of radiopharmaceuticals are outlined, to enable timely and equitable patient access to nuclear medicine procedures worldwide. In the face of disruptions to global supply chains by the coronavirus disease 2019 outbreak, renewed focus on ensuring a reliable supply of radiopharmaceuticals is a major priority for nuclear medicine practice globally.
Collapse
Affiliation(s)
| | - Elizabeth Bailey
- Department of Nuclear Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia
| | - Vijay Kumar
- Department of Nuclear Medicine and PET, Westmead Hospital and Children's Hospital at Westmead, and University of Sydney, New South Wales, Australia
| | - Sally W Schwarz
- Washington University School of Medicine, St Louis, Missouri
| | - Hee-Seung Bom
- Department of Nuclear Medicine, Chonnam National University Hwasun Hospital, Jeollanam, Korea
| | - Jun Hatazawa
- Department of Quantum Cancer Therapy, Research Center for Nuclear Physics, Osaka University, Osaka, Japan
| | - Diana Paez
- Nuclear Medicine and Diagnostic Imaging Section, International Atomic Energy Agency, Vienna, Austria
| | - Pilar Orellana
- Nuclear Medicine and Diagnostic Imaging Section, International Atomic Energy Agency, Vienna, Austria
| | - Lizette Louw
- Department of Nuclear Medicine, Charlotte Maxeke Johannesburg Academic Hospital and University of Witwatersrand, Johannesburg, South Africa
| | - Fernando Mut
- Nuclear Medicine Service, Italian Hospital, Montevideo, Uruguay
| | - Hiroki Kato
- Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Arturo Chiti
- Department of Biomedical Sciences, Humanitas University, and Nuclear Medicine Unit, Humanitas Research Hospital-IRCCS, Milan, Italy
| | - Savvas Frangos
- Department of Nuclear Medicine, Bank of Cyprus Oncology Center, Nicosia, Cyprus
| | - Frederic Fahey
- Department of Radiology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts
| | - Gary Dillehay
- Department of Radiology, Division of Nuclear Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois
| | - Seung J Oh
- Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
| | - Dong S Lee
- Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea
| | - Sze-Ting Lee
- Department of Molecular Imaging and Therapy, Austin Health; University of Melbourne; Olivia Newton-John Cancer Research Institute, and School of Cancer Medicine, La Trobe University, Melbourne, Australia
| | - Rodolfo Nunez-Miller
- Nuclear Medicine and Diagnostic Imaging Section, International Atomic Energy Agency, Vienna, Austria.,Excel Diagnostics and Nuclear Oncology Center, Houston, Texas
| | - Guru Bandhopadhyaya
- Department of Nuclear Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India; and
| | - Prasanta K Pradhan
- Department of Nuclear Medicine, Sanjay Gandhi Post Graduate Institute of Nuclear Medicine, Lucknow, India
| | - Andrew M Scott
- Department of Molecular Imaging and Therapy, Austin Health; University of Melbourne; Olivia Newton-John Cancer Research Institute, and School of Cancer Medicine, La Trobe University, Melbourne, Australia
| |
Collapse
|
14
|
Abstract
Molecular imaging is a non-invasive process that enables the visualization, characterization, and quantitation of biological processes at the molecular and cellular level. With the emergence of theragnostic agents to diagnose and treat disease for personalized medicine there is a growing need for matched pairs of isotopes. Matched pairs offer the unique opportunity to obtain patient specific information from SPECT or PET diagnostic studies to quantitate in vivo function or receptor density to inform and tailor therapeutic treatment. There are several isotopes of arsenic that have emissions suitable for either or both diagnostic imaging and radiotherapy. Their half-lives are long enough to pair them with peptides and antibodies which take longer to reach maximum uptake to facilitate improved patient pharmacokinetics and dosimetry then can be obtained with shorter lived radionuclides. Arsenic-72 even offers availability from a generator that can be shipped to remote sites and thus enhances availability. Arsenic has a long history as a diagnostic agent, but until recently has suffered from limited availability, lack of suitable chelators, and concerns about toxicity have inhibited its use in nuclear medicine. However, new production methods and novel chelators are coming online and the use of radioarsenic in the pico and nanomolar scale is well below the limits associated with toxicity. This manuscript will review the production routes, separation chemistry, radiolabeling techniques and in vitro/in vivo studies of three medically relevant isotopes of arsenic (arsenic-74, arsenic-72, and arsenic-77).
Collapse
Affiliation(s)
- Vanessa A Sanders
- Collider Accelerator Department, Brookhaven National Laboratory, Upton, NY 11973, USA
| | - Cathy S Cutler
- Collider Accelerator Department, Brookhaven National Laboratory, Upton, NY 11973, USA.
| |
Collapse
|
15
|
Abstract
Nuclear medicine has come a long way since 2007 when Adrian Nunn pointed out the approval of radiopharmaceuticals was at an all-time low with all the major radiopharmaceutical agents in use having been approved over 10 years ago. Challenges being the prohibitively high cost of drug development and the large number of drugs failing in clinical trials. Proceed to today where molecular imaging is fast-tracking the drug discovery process by reducing both the time and cost to screen candidates by quantitating the drugs effect on the target and toxicity to normal tissues. Nuclear medicine is now leading medical practice in personalized medicine using the theragnostic approach. Theragnostics is defined as the use of molecular diagnostic techniques in real time to stratify patients to guide treatment decisions such as the choice of drug, the dose of administration, and the timing of drug delivery for a given patient. Enabling visualization and quantitation of in vivo function of the whole body and thus patient heterogeneity and variability informs the physician on how to treat an individual patient. Recent successes such as the Food and Drug Administration approval of Lutathera and NETSPOT have resulted in an increasing number of pharmaceutical companies pursing theragnostics further heightened by the purchase of Advanced Accelerator Applications for 3.9 billion by Novartis and Endocyte, Inc for 2.1 billion. Theragnostics are further aiding drug development by showing which agents are most viable and reducing the overall cost of bringing a drug to clinical trials and regulatory approval. This is indeed a renaissance for nuclear medicine in which the acceptance of imaging to inform and monitor therapy has been embraced and even required by the Food and Drug Administration for the clinical evaluation of targeted therapeutic radiopharmaceuticals showing there is indeed a viable business model for targeted theragnostic radiopharmaceuticals and personalized medicine.
Collapse
Affiliation(s)
- Cathy S Cutler
- Collider Accelerator Department, Brookhaven National Laboratory, Upton, NY.
| |
Collapse
|
16
|
Fitzsimmons J, Abraham A, Catalano D, Younes A, Cutler CS, Medvedev D. Evaluation of Inorganic Ion Exchange Materials for Purification of 225Ac from Thorium and Radium Radioisotopes. J Med Imaging Radiat Sci 2019. [DOI: 10.1016/j.jmir.2019.11.040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
17
|
Coenen HH, Gee AD, Adam M, Antoni G, Cutler CS, Fujibayashi Y, Jeong JM, Mach RH, Mindt TL, Pike VW, Windhorst AD. Open letter to journal editors on: International consensus radiochemistry nomenclature guidelines. J Labelled Comp Radiopharm 2019; 61:402-404. [PMID: 29331022 DOI: 10.1002/jlcr.3604] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2017] [Accepted: 01/03/2018] [Indexed: 11/09/2022]
Affiliation(s)
| | | | | | | | | | | | | | | | - Thomas L Mindt
- Ludwig Boltzmann Institute Applied Diagnostics, Vienna, Austria
| | | | | |
Collapse
|
18
|
Fitzsimmons J, Foley B, Torre B, Wilken M, Cutler CS, Mausner L, Medvedev D. Optimization of Cation Exchange for the Separation of Actinium-225 from Radioactive Thorium, Radium-223 and Other Metals. Molecules 2019; 24:molecules24101921. [PMID: 31109077 PMCID: PMC6571705 DOI: 10.3390/molecules24101921] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2019] [Revised: 05/15/2019] [Accepted: 05/16/2019] [Indexed: 11/16/2022] Open
Abstract
Actinium-225 (225Ac) can be produced with a linear accelerator by proton irradiation of a thorium (Th) target, but the Th also underdoes fission and produces 400 other radioisotopes. No research exists on optimization of the cation step for the purification. The research herein examines the optimization of the cation exchange step for the purification of 225Ac. The following variables were tested: pH of load solution (1.5–4.6); rinse steps with various concentrations of HCl, HNO3, H2SO4, and combinations of HCl and HNO3; various thorium chelators to block retention; MP50 and AG50 resins; and retention of 20–45 elements with different rinse sequences. The research indicated that HCl removes more isotopes earlier than HNO3, but that some elements, such as barium and radium, could be eluted with ≥2.5 M HNO3. The optimal pH of the load solution was 1.5–2.0, and the optimized rinse sequence was five bed volumes (BV) of 1 M citric acid pH 2.0, 3 BV of water, 3 BV of 2 M HNO3, 6 BV of 2.5 M HNO3 and 20 BV of 6 M HNO3. The sequence recovered >90% of 225Ac with minimal 223Ra and thorium present.
Collapse
Affiliation(s)
- Jonathan Fitzsimmons
- Isotope Production Laboratory, Collider-Accelerator Division, Brookhaven National Laboratory, Upton, NY 11973, USA.
| | - Bryan Foley
- Department of Biology, Chemistry, and Geoscience, Fairmont State University, Fairmont, WV 26554, USA.
| | - Bryna Torre
- Department of Chemistry, University at Buffalo, the State University of New York, Buffalo, NY 14260, USA.
| | - Megan Wilken
- Department of Chemistry, Elizabeth City State University, Elizabeth City, NC 27909, USA.
| | - Cathy S Cutler
- Isotope Production Laboratory, Collider-Accelerator Division, Brookhaven National Laboratory, Upton, NY 11973, USA.
| | - Leonard Mausner
- Isotope Production Laboratory, Collider-Accelerator Division, Brookhaven National Laboratory, Upton, NY 11973, USA.
| | - Dmitri Medvedev
- Isotope Production Laboratory, Collider-Accelerator Division, Brookhaven National Laboratory, Upton, NY 11973, USA.
| |
Collapse
|
19
|
Coenen HH, Gee AD, Adam M, Antoni G, Cutler CS, Fujibayashi Y, Jeong JM, Mach RH, Mindt TL, Pike VW, Windhorst AD. Open letter to journal editors on: International Consensus Radiochemistry Nomenclature Guidelines. EJNMMI Radiopharm Chem 2019; 4:7. [PMID: 31659484 PMCID: PMC6465410 DOI: 10.1186/s41181-018-0047-y] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2018] [Accepted: 08/07/2018] [Indexed: 11/30/2022] Open
Affiliation(s)
| | | | | | | | | | | | | | | | - Thomas L Mindt
- Ludwig Boltzmann Institute of Applied Diagnostics, Vienna, Austria
| | | | | |
Collapse
|
20
|
Fitzsimmons J, Abraham A, Catalano D, Younes A, Cutler CS, Medvedev D. Evaluation of Inorganic Ion Exchange Materials for Purification of 225Ac from Thorium and Radium Radioisotopes. J Med Imaging Radiat Sci 2019. [DOI: 10.1016/j.jmir.2019.03.035] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
21
|
Coenen HH, Gee AD, Adam M, Antoni G, Cutler CS, Fujibayashi Y, Jeong JM, Mach RH, Mindt TL, Pike VW, Windhorst AD. Open letter to journal editors on: International Consensus Radiochemistry Nomenclature Guidelines. Clin Transl Imaging 2019. [DOI: 10.1007/s40336-018-00310-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
22
|
DeGraffenreid AJ, Medvedev DG, Phelps TE, Gott MD, Smith SV, Jurisson SS, Cutler CS. Cross-section measurements and production of 72Se with medium to high energy protons using arsenic containing targets. RADIOCHIM ACTA 2019. [DOI: 10.1515/ract-2018-2931] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Abstract
Experiments were performed to evaluate production of 72Se, parent radionuclide of the positron emitter 72As, at high energy at the Brookhaven Linac Isotope Producer (BLIP). Excitation functions for 75As(p, xn)72/75Se in the 52-105 MeV energy range were measured by irradiating thin gallium arsenide (GaAs) wafers. Maximum cross section value for the natAs(p, 4n)72Se reaction in the energy range was 103±9 mb at 52±1 MeV. Production size GaAs and arsenic metal (As°) targets were irradiated with 136 μA and 165 μA beam current possessing an initial Linac energy of 117 MeV. A total of 3.77±0.1 GBq (102±3 mCi) of 72Se was produced from a GaAs target at a calculated target entrance energy of 105.4 MeV, and 13.8±0.3 GBq (373±8 mCi) of 72Se from an As° target at a calculated incident energy of 49.5 MeV irradiated for 116.5 h and 68.9 h, respectively.
Collapse
Affiliation(s)
| | - Dmitri G. Medvedev
- Collider Accelerator Department , Brookhaven National Laboratory , Upton, NY 11973 , USA
| | - Timothy E. Phelps
- Department of Chemistry , University of Missouri , Columbia, MO 65211 , USA
| | - Matthew D. Gott
- Department of Chemistry , University of Missouri , Columbia, MO 65211 , USA
| | - Suzanne V. Smith
- Collider Accelerator Department , Brookhaven National Laboratory , Upton, NY 11973 , USA
| | - Silvia S. Jurisson
- Department of Chemistry , University of Missouri , Columbia, MO 65211 , USA
| | - Cathy S. Cutler
- Collider Accelerator Department , Brookhaven National Laboratory , Upton, NY 11973 , USA
| |
Collapse
|
23
|
Feng Y, Phipps MD, Phelps TE, Okoye NC, Baumeister JE, Wycoff DE, Dorman EF, Wooten AL, Vlasenko V, Berendzen AF, Wilbur DS, Hoffman TJ, Cutler CS, Ketring AR, Jurisson SS. Evaluation of 72Se/ 72As generator and production of 72Se for supplying 72As as a potential PET imaging radionuclide. Appl Radiat Isot 2019; 143:113-122. [PMID: 30408634 DOI: 10.1016/j.apradiso.2018.10.026] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2018] [Revised: 10/22/2018] [Accepted: 10/29/2018] [Indexed: 11/23/2022]
Abstract
Positron-emitting 72As is the PET imaging counterpart for beta-emitting 77As. Its parent, no carrier added (n.c.a.) 72Se, was produced for a 72Se/72As generator by irradiating an enriched 7°Ge metal-graphite target via the 70Ge(α, 2 n)72Se reaction. Target dissolution used a fast, environmentally friendly method with 93% radioactivity recovery. Chromatographic parameters of the 72Se/72As generator were evaluated, the eluted n.c.a. 72As was characterized with a phantom imaging study, and the previously reported trithiol and aryl-dithiol ligand systems were radiolabeled with the separated n.c.a. 72As in high yield.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | - Alan R Ketring
- University of Missouri Research Reactor Center, Columbia, MO, USA
| | - Silvia S Jurisson
- University of Missouri, Columbia, MO, USA; University of Missouri Research Reactor Center, Columbia, MO, USA.
| |
Collapse
|
24
|
Fitzsimmons J, Torre B, Foley B, Copping R, Hill DE, Mirzadeh S, Cutler CS, Mausner L, Medvedev D. Evaluation of SynPhase Lanterns for capturing Ac-225 from bulk thorium. J Radioanal Nucl Chem 2018. [DOI: 10.1007/s10967-018-5997-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
25
|
Feng Y, DeGraffenreid AJ, Phipps MD, Rold TL, Okoye NC, Gallazzi FA, Barnes CL, Cutler CS, Ketring AR, Hoffman TJ, Jurisson SS. A trithiol bifunctional chelate for 72,77As: A matched pair theranostic complex with high in vivo stability. Nucl Med Biol 2018; 61:1-10. [DOI: 10.1016/j.nucmedbio.2018.03.001] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2017] [Revised: 02/13/2018] [Accepted: 03/04/2018] [Indexed: 12/21/2022]
|
26
|
Coenen HH, Gee AD, Adam M, Antoni G, Cutler CS, Fujibayashi Y, Jeong JM, Mach RH, Mindt TL, Pike VW, Windhorst AD. Letter to the Editor: International Consensus Radiochemistry Nomenclature Guidelines. Curr Radiopharm 2018; 11:73-75. [PMID: 29624156 DOI: 10.2174/187447101101180404111248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
| | | | | | | | | | | | | | - Robert H Mach
- University of Pennsylvania, Philadelphia, United States
| | - Thomas L Mindt
- Ludwig Boltzmann Institute Applied Diagnostics, Vienna, Austria
| | - Victor W Pike
- National Institute of Mental Health, Bethesda, United States
| | | |
Collapse
|
27
|
Fitzsimmons J, Muench L, Cutler CS. Fishing for Isotopes: Capturing Beryllium-7 from Brookhaven LINAC Isotope Producer's 300 gallons of Cooling Water. ACS Omega 2018; 3:3228-3234. [PMID: 31458580 PMCID: PMC6641255 DOI: 10.1021/acsomega.7b01757] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 11/09/2017] [Accepted: 01/25/2018] [Indexed: 06/10/2023]
Abstract
The ability of capturing metals and/or radionuclides from large amounts of water is important for radioisotope waste treatment and environmental cleanup. We have developed an approach that rapidly optimizes the capturing of radioisotopes in large-volume aqueous environments. The approach was scaled up to capture beryllium-7 from 300 gallons of cooling water associated with a linear accelerator. Solid supports with the functional groups sulfonic acid, iminodiacetate, pyridine amine, pyridine amine acid, or quaternary amine were incubated in the cooling water for 1 week. One sulfonic acid solid support was able to capture 2.1 mCi of Be-7. Subsequent studies with the sulfonic acid solid support focused on the uptake over time of Be-7, scale-up of capturing Be-7, and subsequent purification of Be-7. The uptake over time of Be-7 was found to be linear in the first 24 h, with an equation of Y = 4.11X (% uptake/time (h)) (R 2 = 0.998). The uptake of Be-7 reached the maximum at 24 h and was identical to the uptake at 168 h. To purify Be-7, the optimal purification approach was to release the Be-7 from the solid support with 10 M HCl, which could be immediately passed through an AG1 resin to remove radioimpurities. The radiopurity of the purified Be-7 was greater than 99%, and this method was used to purify 65 mCi of the isotope.
Collapse
|
28
|
Coenen HH, Gee AD, Adam M, Antoni G, Cutler CS, Fujibayashi Y, Jeong JM, Mach RH, Mindt TL, Pike VW, Windhorst AD. Open letter to journal editors on: international consensus radiochemistry nomenclature guidelines. J Radioanal Nucl Chem 2018. [DOI: 10.1007/s10967-017-5693-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
29
|
Coenen HH, Gee AD, Adam M, Antoni G, Cutler CS, Fujibayashi Y, Jeong JM, Mach RH, Mindt TL, Pike VW, Windhorst AD. Open letter to journal editors on: International Consensus Radiochemistry Nomenclature Guidelines. Ann Nucl Med 2018; 32:236-238. [PMID: 29423765 PMCID: PMC5852186 DOI: 10.1007/s12149-018-1238-z] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2018] [Accepted: 01/24/2018] [Indexed: 11/30/2022]
Affiliation(s)
| | | | | | | | | | | | | | | | - Thomas L Mindt
- Ludwig Boltzmann Institute Applied Diagnostics, Vienna, Austria
| | | | | |
Collapse
|
30
|
Turcotte LM, DeFor TE, Newell LF, Cutler CS, Verneris MR, Wu J, Howard A, MacMillan ML, Antin JH, Vercellotti GM, Slungaard A, Blazar BR, Weisdorf DJ, Panoskaltsis-Mortari A, Holtan SG. Donor and recipient plasma follistatin levels are associated with acute GvHD in Blood and Marrow Transplant Clinical Trials Network 0402. Bone Marrow Transplant 2017; 53:64-68. [PMID: 29058696 PMCID: PMC5752567 DOI: 10.1038/bmt.2017.236] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2017] [Revised: 08/25/2017] [Accepted: 09/13/2017] [Indexed: 12/13/2022]
Abstract
Follistatin is an angiogenic factor elevated in the circulation after
allogeneic hematopoietic cell transplantation (HCT). Elevations in follistatin
plasma concentrations are associated with the onset of and poor survival after
acute graft versus host disease (aGVHD). Using data from the Blood and Marrow
Transplant Clinical Trials Network 0402 study (n=247), we sought to
further quantify the longitudinal associations between plasma follistatin levels
in transplant recipients, as well as baseline HCT donor follistatin levels, and
allogeneic HCT outcomes. Higher recipient baseline follistatin levels were
predictive of development of aGVHD (P=0.04). High donor
follistatin levels were also associated with the incidence of aGVHD
(P<0.01). Elevated follistatin levels on day 28 were
associated with the onset of grade II–IV aGVHD prior to day 28, higher
one-year non-relapse mortality, (NRM), and lower overall survival (OS). In
multivariate analyses, individuals with follistatin levels >1088 pg/mL at day
28 had a four-fold increased risk for NRM (RR=4.3, 95% CI
1.9–9.9, P<0.01) and a nearly three-fold increased
overall risk for mortality (RR=2.8, 95% CI 1.5–5.2,
P<0.01). Given the multiple roles of follistatin in
tissue inflammation and repair, and the confirmation that this biomarker is
predictive of important HCT outcomes, the pathobiology of these relationships
need further study.
Collapse
Affiliation(s)
- L M Turcotte
- Division of Pediatric Hematology/Oncology, University of Minnesota, Minneapolis, MN, USA
| | - T E DeFor
- Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN, USA.,Biostatistics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA
| | - L F Newell
- Center for Hematologic Malignancies, Oregon Health & Science University, Portland, OR, USA
| | - C S Cutler
- Hematologic Malignancy Program, Dana Farber Cancer Institute, Boston, MA, USA
| | - M R Verneris
- Pediatric BMT and Cell Therapy, University of Colorado Anschutz Medical Campus and Children's Hospital, Denver, CO, USA
| | - J Wu
- The EMMES Corporation, Rockville, MD, USA
| | - A Howard
- Center for International Blood and Marrow Transplant Research, Minneapolis, MN, USA
| | - M L MacMillan
- Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN, USA
| | - J H Antin
- Hematologic Malignancy Program, Dana Farber Cancer Institute, Boston, MA, USA
| | - G M Vercellotti
- Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN, USA
| | - Ane Slungaard
- Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN, USA
| | - B R Blazar
- Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN, USA
| | - D J Weisdorf
- Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN, USA
| | | | - S G Holtan
- Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN, USA
| |
Collapse
|
31
|
Coenen HH, Gee AD, Adam M, Antoni G, Cutler CS, Fujibayashi Y, Jeong JM, Mach RH, Mindt TL, Pike VW, Windhorst AD. Consensus nomenclature rules for radiopharmaceutical chemistry - Setting the record straight. Nucl Med Biol 2017; 55:v-xi. [PMID: 29074076 DOI: 10.1016/j.nucmedbio.2017.09.004] [Citation(s) in RCA: 140] [Impact Index Per Article: 20.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2017] [Accepted: 09/22/2017] [Indexed: 10/18/2022]
Abstract
Over recent years, within the community of radiopharmaceutical sciences, there has been an increased incidence of incorrect usage of established scientific terms and conventions, and even the emergence of 'self-invented' terms. In order to address these concerns, an international Working Group on 'Nomenclature in Radiopharmaceutical Chemistry and related areas' was established in 2015 to achieve clarification of terms and to generate consensus on the utilisation of a standardised nomenclature pertinent to the field. Upon open consultation, the following consensus guidelines were agreed, which aim to.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - Thomas L Mindt
- Ludwig Boltzmann Institute Applied Diagnostics, Vienna, Austria
| | | | | |
Collapse
|
32
|
Balkin ER, Gagnon K, Dorman E, Emery R, Li Y, Wooten AL, Smith BE, Strong KT, Pauzauskie PJ, Fassbender ME, Cutler CS, Ketring AR, Jurisson SS, Wilbur DS. Scale-up of high specific activity 186gRe production using graphite-encased thick 186W targets and demonstration of an efficient target recycling process. RADIOCHIM ACTA 2017. [DOI: 10.1515/ract-2017-2780] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Abstract
Production of high specific activity 186gRe is of interest for development of theranostic radiopharmaceuticals. Previous studies have shown that high specific activity 186gRe can be obtained by cyclotron irradiation of enriched 186W via the 186W(d,2n)186gRe reaction, but most irradiations were conducted at low beam currents and for short durations. In this investigation, enriched 186W metal targets were irradiated at high incident deuteron beam currents to demonstrate production rates and contaminants produced when using thick targets. Full-stopping thick targets, as determined using SRIM, were prepared by uniaxial pressing of powdered natural abundance W metal or 96.86% enriched 186W metal encased between two layers of graphite flakes for target material stabilization. An assessment of structural integrity was made on each target preparation. To assess the performance of graphite-encased thick 186W metal targets, along with the impact of encasing on the separation chemistry, targets were first irradiated using a 22 MeV deuteron beam for 10 min at 10, 20, and 27 μA, with an estimated nominal deuteron energy of 18.7 MeV on the 186W target material (after energy degradation correction from top graphite layer). Gamma-ray spectrometry was performed post EOB on all targets to assess production yields and radionuclidic byproducts. The investigation also evaluated a method to recover and recycle enriched target material from a column isolation procedure. Material composition analyses of target materials, pass-through/wash solutions and recycling process isolates were conducted with SEM, FTIR, XRD, EDS and ICP-MS spectrometry. To demonstrate scaled-up production, a graphite-encased 186W target made from recycled 186W was irradiated for ~2 h with 18.7 MeV deuterons at a beam current of 27 μA to provide 0.90 GBq (24.3 mCi) of 186gRe, decay-corrected to the end of bombardment. ICP-MS analysis of the isolated 186gRe solution provided data that indicated the specific activity of 186gRe in this scaled-up production run was 2.6±0.5 GBq/μg (70±10 Ci/mg).
Collapse
Affiliation(s)
- Ethan R. Balkin
- Department of Radiation Oncology , University of Washington , Seattle, WA 98195 , USA
| | - Katherine Gagnon
- Department of Radiation Oncology , University of Washington , Seattle, WA 98195 , USA
| | - Eric Dorman
- Department of Radiation Oncology , University of Washington , Seattle, WA 98195 , USA
| | - Robert Emery
- Department of Radiation Oncology , University of Washington , Seattle, WA 98195 , USA
| | - Yawen Li
- Department of Radiation Oncology , University of Washington , Seattle, WA 98195 , USA
| | - A. Lake Wooten
- Department of Radiation Oncology , University of Washington , Seattle, WA 98195 , USA
| | - Bennett E. Smith
- Chemistry Department , University of Washington , Seattle, WA 98195 , USA
| | - Kevin T. Strong
- Materials Science and Engineering Department , University of Washington , Seattle, WA 98195 , USA
| | - Peter J. Pauzauskie
- Materials Science and Engineering Department , University of Washington , Seattle, WA 98195 , USA
| | | | - Cathy S. Cutler
- Medical Isotope Research and Production Program , Brookhaven National Laboratory , Upton, NY 11973 , USA
- University of Missouri Research Reactor Center , Columbia, MO 65211 , USA
| | - Alan R. Ketring
- University of Missouri Research Reactor Center , Columbia, MO 65211 , USA
| | - Silvia S. Jurisson
- Department of Chemistry , University of Missouri , Columbia , MO 65211, USA
| | - D. Scott Wilbur
- Department of Radiation Oncology , University of Washington , Seattle, WA 98195 , USA
| |
Collapse
|
33
|
Radchenko V, Mastren T, Meyer CAL, Ivanov AS, Bryantsev VS, Copping R, Denton D, Engle JW, Griswold JR, Murphy K, Wilson JJ, Owens A, Wyant L, Birnbaum ER, Fitzsimmons J, Medvedev D, Cutler CS, Mausner LF, Nortier MF, John KD, Mirzadeh S, Fassbender ME. Radiometric evaluation of diglycolamide resins for the chromatographic separation of actinium from fission product lanthanides. Talanta 2017; 175:318-324. [PMID: 28841997 DOI: 10.1016/j.talanta.2017.07.057] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2017] [Revised: 07/18/2017] [Accepted: 07/19/2017] [Indexed: 11/19/2022]
Abstract
Actinium-225 is a potential Targeted Alpha Therapy (TAT) isotope. It can be generated with high energy (≥ 100MeV) proton irradiation of thorium targets. The main challenge in the chemical recovery of 225Ac lies in the separation from thorium and many fission by-products most importantly radiolanthanides. We recently developed a separation strategy based on a combination of cation exchange and extraction chromatography to isolate and purify 225Ac. In this study, actinium and lanthanide equilibrium distribution coefficients and column elution behavior for both TODGA (N,N,N',N'-tetra-n-octyldiglycolamide) and TEHDGA (N,N,N',N'-tetrakis-2-ethylhexyldiglycolamide) were determined. Density functional theory (DFT) calculations were performed and were in agreement with experimental observations providing the foundation for understanding of the selectivity for Ac and lanthanides on different DGA (diglycolamide) based resins. The results of Gibbs energy (ΔGaq) calculations confirm significantly higher selectivity of DGA based resins for LnIII over AcIII in the presence of nitrate. DFT calculations and experimental results reveal that Ac chemistry cannot be predicted from lanthanide behavior under comparable circumstances.
Collapse
Affiliation(s)
- Valery Radchenko
- Chemistry Division, Los Alamos National Laboratory, P.O. Box 1663, Los Alamos, NM 87545, USA; Life Science Division, TRIUMF, 4004 Wesbrook Mall, Vancouver, BC V6T 2A3, Canada
| | - Tara Mastren
- Chemistry Division, Los Alamos National Laboratory, P.O. Box 1663, Los Alamos, NM 87545, USA
| | - Catherine A L Meyer
- Chemistry Division, Los Alamos National Laboratory, P.O. Box 1663, Los Alamos, NM 87545, USA
| | - Alexander S Ivanov
- Chemical Sciences Division, Oak Ridge National Laboratory, Oak Ridge, TN 37831, USA
| | | | - Roy Copping
- Nuclear Security and Isotope Technology Division, Oak Ridge National Laboratory, Oak Ridge, TN 37831, USA
| | - David Denton
- Nuclear Security and Isotope Technology Division, Oak Ridge National Laboratory, Oak Ridge, TN 37831, USA
| | - Jonathan W Engle
- Chemistry Division, Los Alamos National Laboratory, P.O. Box 1663, Los Alamos, NM 87545, USA; Department of Medical Physics, University of Wisconsin, Madison, WI 53705, USA
| | - Justin R Griswold
- Nuclear Security and Isotope Technology Division, Oak Ridge National Laboratory, Oak Ridge, TN 37831, USA
| | - Karen Murphy
- Nuclear Security and Isotope Technology Division, Oak Ridge National Laboratory, Oak Ridge, TN 37831, USA
| | - Justin J Wilson
- Chemistry Division, Los Alamos National Laboratory, P.O. Box 1663, Los Alamos, NM 87545, USA; Department of Chemistry&Chemical Biology, Cornell University, Ithaca, NY 14853, USA
| | - Allison Owens
- Nuclear Security and Isotope Technology Division, Oak Ridge National Laboratory, Oak Ridge, TN 37831, USA
| | - Lance Wyant
- Chemical Sciences Division, Oak Ridge National Laboratory, Oak Ridge, TN 37831, USA
| | - Eva R Birnbaum
- Chemistry Division, Los Alamos National Laboratory, P.O. Box 1663, Los Alamos, NM 87545, USA
| | - Jonathan Fitzsimmons
- Collider-Accelerator Department, Brookhaven National Laboratory, Bldg 801, Upton, NY 11973, USA
| | - Dmitri Medvedev
- Collider-Accelerator Department, Brookhaven National Laboratory, Bldg 801, Upton, NY 11973, USA
| | - Cathy S Cutler
- Collider-Accelerator Department, Brookhaven National Laboratory, Bldg 801, Upton, NY 11973, USA
| | - Leonard F Mausner
- Collider-Accelerator Department, Brookhaven National Laboratory, Bldg 801, Upton, NY 11973, USA
| | - Meiring F Nortier
- Chemistry Division, Los Alamos National Laboratory, P.O. Box 1663, Los Alamos, NM 87545, USA
| | - Kevin D John
- Chemistry Division, Los Alamos National Laboratory, P.O. Box 1663, Los Alamos, NM 87545, USA
| | - Saed Mirzadeh
- Nuclear Security and Isotope Technology Division, Oak Ridge National Laboratory, Oak Ridge, TN 37831, USA
| | - Michael E Fassbender
- Chemistry Division, Los Alamos National Laboratory, P.O. Box 1663, Los Alamos, NM 87545, USA.
| |
Collapse
|
34
|
Radchenko V, Engle JW, Medvedev DG, Maassen JM, Naranjo CM, Unc GA, Meyer CA, Mastren T, Brugh M, Mausner L, Cutler CS, Birnbaum ER, John KD, Nortier FM, Fassbender ME. Proton-induced production and radiochemical isolation of 44Ti from scandium metal targets for 44Ti/44Sc generator development. Nucl Med Biol 2017; 50:25-32. [DOI: 10.1016/j.nucmedbio.2017.03.006] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2016] [Revised: 02/01/2017] [Accepted: 03/23/2017] [Indexed: 12/14/2022]
|
35
|
Chen YB, Wang T, Hemmer MT, Brady C, Couriel DR, Alousi A, Pidala J, Urbano-Ispizua A, Choi SW, Nishihori T, Teshima T, Inamoto Y, Wirk B, Marks DI, Abdel-Azim H, Lehmann L, Yu L, Bitan M, Cairo MS, Qayed M, Salit R, Gale RP, Martino R, Jaglowski S, Bajel A, Savani B, Frangoul H, Lewis ID, Storek J, Askar M, Kharfan-Dabaja MA, Aljurf M, Ringden O, Reshef R, Olsson RF, Hashmi S, Seo S, Spitzer TR, MacMillan ML, Lazaryan A, Spellman SR, Arora M, Cutler CS. GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes. Bone Marrow Transplant 2016; 52:400-408. [PMID: 27941764 PMCID: PMC5332289 DOI: 10.1038/bmt.2016.265] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2016] [Revised: 08/12/2016] [Accepted: 08/28/2016] [Indexed: 11/15/2022]
Abstract
Using the Center for International Blood and Marrow Transplant Research (CIBMTR) registry, we analyzed 1,404 UCBT patients [single (< 18 years) = 810, double (≥ 18 years) = 594] with acute leukemia to define the incidence of acute and chronic graft-vs.-host disease (GVHD), analyze clinical risk factors and investigate outcomes. After single UCBT, 100-day incidence of grades II–IV aGVHD was 39% (95% CI, 36–43%), grades III–IV aGVHD was 18% (95% CI, 15–20%), and 1-year cGVHD was 27% (95% CI, 24–30%). After double UCBT, 100-day incidence of grades II–IV aGVHD was 45% (95% CI, 41%–49%), grades III–IV aGVHD was 22% (95% CI, 19–26%), and 1-year cGVHD was 26% (95% CI, 22–29%). For single UCBT, multivariate analysis showed that absence of anti-thymocyte globulin (ATG) was associated with aGVHD, whereas prior aGVHD was associated with cGVHD. For double UCBT, absence of ATG and myeloablative conditioning were associated with aGVHD, while prior aGVHD predicted for cGVHD. Grades III–IV aGVHD led to worse survival whereas cGVHD had no significant effect on disease-free or overall survival. GVHD is prevalent after UCBT with severe aGVHD leading to higher mortality. Future research in UCBT should prioritize prevention of GVHD.
Collapse
Affiliation(s)
- Y-B Chen
- Massachusetts General Hospital, Boston, MA, USA
| | - T Wang
- Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.,Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI, USA
| | - M T Hemmer
- Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA
| | - C Brady
- Center for International Blood and Marrow Transplant Research, National Marrow Donor Program/Be The Match, Minneapolis, MN, USA
| | - D R Couriel
- Utah Blood and Marrow Transplant Program, Adults, Salt Lake City, UT, USA
| | - A Alousi
- Division of Cancer Medicine, Department of Stem Cell Transplantation, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - J Pidala
- H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - A Urbano-Ispizua
- Department of Hematology, Hospital Clinic, University of Barcelona, IDIBAPS and Institute of Research Josep Carreras, Barcelona, Spain
| | - S W Choi
- The University of Michigan, Ann Arbor, MI, USA
| | - T Nishihori
- Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - T Teshima
- Kyushu University Hospital, Fukuoka, Japan
| | - Y Inamoto
- Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan
| | - B Wirk
- Division of Bone Marrow Transplant, Seattle Cancer Care Alliance, Seattle, WA, USA
| | - D I Marks
- Adult Bone Marrow Transplant, University Hospitals Bristol NHS Trust, Bristol, UK
| | - H Abdel-Azim
- Division of Hematology, Oncology and Blood and Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA, USA
| | - L Lehmann
- Dana-Farber Cancer Institute/Boston Children's Hospital, Boston, MA, USA
| | - L Yu
- Division of Hematology/Oncology and HSCT, The Center for Cancer and Blood Disorders, Children's Hospital/Louisiana State University Medical Center, New Orleans, LA, USA
| | - M Bitan
- Department of Pediatric Hematology/Oncology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel
| | - M S Cairo
- Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Department of Pediatrics, New York Medical College, Valhalla, NY, USA
| | - M Qayed
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, Australia
| | - R Salit
- Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - R P Gale
- Hematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, UK
| | - R Martino
- Division of Clinical Hematology, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain
| | - S Jaglowski
- Division of Hematology, The Ohio State University Medical Center, Columbus, OH, USA
| | - A Bajel
- Royal Melbourne Hospital City Campus, Melbourne, Victoria, Australia
| | - B Savani
- Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
| | - H Frangoul
- Division of Hematology-Oncology, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - I D Lewis
- Haematology and Bone Marrow Transplant Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia
| | - J Storek
- Department of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - M Askar
- Baylor University Medical Center, Dallas, TX, USA
| | - M A Kharfan-Dabaja
- Department of Blood and Marrow Transplantation, H Lee Mofitt Cancer Center and Research Institute, Tampa, FL, USA
| | - M Aljurf
- Department of Oncology, King Faisal Specialist Hospital Center and Research, Riyadh, Saudi Arabia
| | - O Ringden
- Division of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.,Centre for Clinical Research Sormland, Uppsala University, Uppsala, Sweden
| | - R Reshef
- Blood and Marrow Transplantation Program and Columbia Center for Translational Immunology, Columbia University Medical Center, New York, NY, USA
| | - R F Olsson
- Division of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.,Centre for Clinical Research Sormland, Uppsala University, Uppsala, Sweden
| | - S Hashmi
- Mayo Clinic Rochester, Rochester, MN, USA
| | - S Seo
- National Cancer Research Center, East Hospital, Kashiwa, Chiba, Japan
| | - T R Spitzer
- Massachusetts General Hospital, Boston, MA, USA
| | - M L MacMillan
- University of Minnesota Medical Center, Fairview, Minneapolis, MN, USA
| | - A Lazaryan
- University of Minnesota Medical Center, Fairview, Minneapolis, MN, USA
| | - S R Spellman
- Center for International Blood and Marrow Transplant Research, National Marrow Donor Program/Be The Match, Minneapolis, MN, USA
| | - M Arora
- Division of Hematology, Oncology, Transplantation, Department of Medicine, University of Minnesota Medical Center, Minneapolis, MN, USA
| | - C S Cutler
- Center for Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
| |
Collapse
|
36
|
Balkin ER, Gagnon K, Strong KT, Smith BE, Dorman EF, Emery RC, Pauzauskie PJ, Fassbender ME, Cutler CS, Ketring AR, Jurisson SS, Wilbur DS. Deuteron irradiation of W and WO3 for production of high specific activity 186Re: Challenges associated with thick target preparation. Appl Radiat Isot 2016; 115:197-207. [DOI: 10.1016/j.apradiso.2016.06.021] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2016] [Revised: 06/17/2016] [Accepted: 06/20/2016] [Indexed: 02/04/2023]
|
37
|
Gott MD, Hayes CR, Wycoff DE, Balkin ER, Smith BE, Pauzauskie PJ, Fassbender ME, Cutler CS, Ketring AR, Wilbur DS, Jurisson SS. Accelerator-based production of the 99mTc-186Re diagnostic-therapeutic pair using metal disulfide targets (MoS2, WS2, OsS2). Appl Radiat Isot 2016; 114:159-66. [PMID: 27236832 DOI: 10.1016/j.apradiso.2016.05.024] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2016] [Revised: 05/17/2016] [Accepted: 05/18/2016] [Indexed: 11/18/2022]
Affiliation(s)
- Matthew D Gott
- Department of Chemistry, University of Missouri, Columbia, MO 65211, United States
| | - Connor R Hayes
- Department of Chemistry, University of Missouri, Columbia, MO 65211, United States
| | - Donald E Wycoff
- Department of Chemistry, University of Missouri, Columbia, MO 65211, United States
| | - Ethan R Balkin
- Department of Radiation Oncology, University of Washington, Seattle, WA 98105, United States
| | - Bennett E Smith
- Department of Chemistry, University of Washington, Seattle, WA 98105, United States
| | - Peter J Pauzauskie
- Department of Materials Science and Engineering, University of Washington, Seattle, WA 98105, United States
| | - Michael E Fassbender
- Chemistry Division, Los Alamos National Laboratory, Los Alamos, NM 87545, United States
| | - Cathy S Cutler
- University of Missouri Research Reactor Center, Columbia, MO 65211, United States
| | - Alan R Ketring
- University of Missouri Research Reactor Center, Columbia, MO 65211, United States
| | - D Scott Wilbur
- Department of Radiation Oncology, University of Washington, Seattle, WA 98105, United States
| | - Silvia S Jurisson
- Department of Chemistry, University of Missouri, Columbia, MO 65211, United States.
| |
Collapse
|
38
|
DeGraffenreid AJ, Feng Y, Wycoff DE, Morrow R, Phipps MD, Cutler CS, Ketring AR, Barnes CL, Jurisson SS. Dithiol Aryl Arsenic Compounds as Potential Diagnostic and Therapeutic Radiopharmaceuticals. Inorg Chem 2016; 55:8091-8. [DOI: 10.1021/acs.inorgchem.6b01175] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Affiliation(s)
- Anthony J. DeGraffenreid
- Department of Chemistry and ‡Research Reactor
Center (MURR), University of Missouri, Columbia, Missouri 65211, United States
| | - Yutian Feng
- Department of Chemistry and ‡Research Reactor
Center (MURR), University of Missouri, Columbia, Missouri 65211, United States
| | - Donald E. Wycoff
- Department of Chemistry and ‡Research Reactor
Center (MURR), University of Missouri, Columbia, Missouri 65211, United States
| | - Ryan Morrow
- Department of Chemistry and ‡Research Reactor
Center (MURR), University of Missouri, Columbia, Missouri 65211, United States
| | - Michael D. Phipps
- Department of Chemistry and ‡Research Reactor
Center (MURR), University of Missouri, Columbia, Missouri 65211, United States
| | - Cathy S. Cutler
- Department of Chemistry and ‡Research Reactor
Center (MURR), University of Missouri, Columbia, Missouri 65211, United States
| | - Alan R. Ketring
- Department of Chemistry and ‡Research Reactor
Center (MURR), University of Missouri, Columbia, Missouri 65211, United States
| | - Charles L. Barnes
- Department of Chemistry and ‡Research Reactor
Center (MURR), University of Missouri, Columbia, Missouri 65211, United States
| | - Silvia S. Jurisson
- Department of Chemistry and ‡Research Reactor
Center (MURR), University of Missouri, Columbia, Missouri 65211, United States
| |
Collapse
|
39
|
Zhao Y, Pang B, Luehmann H, Detering L, Yang X, Sultan D, Harpstrite S, Sharma V, Cutler CS, Xia Y, Liu Y. Gold Nanoparticles Doped with (199) Au Atoms and Their Use for Targeted Cancer Imaging by SPECT. Adv Healthc Mater 2016; 5:928-35. [PMID: 26865221 PMCID: PMC4836969 DOI: 10.1002/adhm.201500992] [Citation(s) in RCA: 44] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2015] [Revised: 01/09/2016] [Indexed: 12/18/2022]
Abstract
Gold nanoparticles have been labeled with various radionuclides and extensively explored for single photon emission computed tomography (SPECT) in the context of cancer diagnosis. The stability of most radiolabels, however, still needs to be improved for accurate detection of cancer biomarkers and thereby monitoring of tumor progression and metastasis. Here, the first synthesis of Au nanoparticles doped with (199)Au atoms for targeted SPECT tumor imaging in a mouse triple negative breast cancer (TNBC) model is reported. By directly incorporating (199)Au atoms into the crystal lattice of each Au nanoparticle, the stability of the radiolabel can be ensured. The synthetic procedure also allows for a precise control over both the radiochemistry and particle size. When conjugated with D-Ala1-peptide T-amide, the Au nanoparticles doped with (199)Au atoms can serve as a C-C chemokine receptor 5 (CCR5)-targeted nanoprobe for the sensitive and specific detection of both TNBC and its metastasis in a mouse tumor model.
Collapse
Affiliation(s)
- Yongfeng Zhao
- Department of Radiology, Washington University School of Medicine, St. Louis, MO, 63110, USA
| | - Bo Pang
- The Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, 30332, USA
- Department of Biomedical Engineering, Peking University, Beijing, 100871, P. R. China
| | - Hannah Luehmann
- Department of Radiology, Washington University School of Medicine, St. Louis, MO, 63110, USA
| | - Lisa Detering
- Department of Radiology, Washington University School of Medicine, St. Louis, MO, 63110, USA
| | - Xuan Yang
- The Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, 30332, USA
| | - Deborah Sultan
- Department of Radiology, Washington University School of Medicine, St. Louis, MO, 63110, USA
| | - Scott Harpstrite
- Department of Radiology, Washington University School of Medicine, St. Louis, MO, 63110, USA
| | - Vijay Sharma
- Department of Radiology, Washington University School of Medicine, St. Louis, MO, 63110, USA
| | - Cathy S Cutler
- Research Reactor Center, University of Missouri, Columbia, MO, 65211, USA
| | - Younan Xia
- The Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, 30332, USA
| | - Yongjian Liu
- Department of Radiology, Washington University School of Medicine, St. Louis, MO, 63110, USA
| |
Collapse
|
40
|
Gott MD, DeGraffenreid AJ, Feng Y, Phipps MD, Wycoff DE, Embree MF, Cutler CS, Ketring AR, Jurisson SS. Chromatographic separation of germanium and arsenic for the production of high purity (77)As. J Chromatogr A 2016; 1441:68-74. [PMID: 26947162 DOI: 10.1016/j.chroma.2016.02.074] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2015] [Revised: 02/23/2016] [Accepted: 02/24/2016] [Indexed: 10/22/2022]
Abstract
A simple column chromatographic method was developed to isolate (77)As (94±6% (EtOH/HCl); 74±11 (MeOH)) from germanium for potential use in radioimmunotherapy. The separation of arsenic from germanium was based on their relative affinities for different chromatographic materials in aqueous and organic environments. Using an organic or mixed mobile phase, germanium was selectively retained on a silica gel column as germanate, while arsenic was eluted from the column as arsenate. Subsequently, enriched (76)Ge (98±2) was recovered for reuse by elution with aqueous solution (neutral to basic). Greater than 98% radiolabeling yield of a (77)As-trithiol was observed from methanol separated [(77)As]arsenate [17].
Collapse
Affiliation(s)
- Matthew D Gott
- Department of Chemistry, University of Missouri, Columbia, MO 65211, United States
| | | | - Yutian Feng
- Department of Chemistry, University of Missouri, Columbia, MO 65211, United States
| | - Michael D Phipps
- Department of Chemistry, University of Missouri, Columbia, MO 65211, United States
| | - Donald E Wycoff
- Department of Chemistry, University of Missouri, Columbia, MO 65211, United States
| | - Mary F Embree
- University of Missouri Research Reactor Center, Columbia, MO 65211, United States
| | - Cathy S Cutler
- University of Missouri Research Reactor Center, Columbia, MO 65211, United States
| | - Alan R Ketring
- University of Missouri Research Reactor Center, Columbia, MO 65211, United States
| | - Silvia S Jurisson
- Department of Chemistry, University of Missouri, Columbia, MO 65211, United States.
| |
Collapse
|
41
|
DeGraffenreid AJ, Feng Y, Barnes CL, Ketring AR, Cutler CS, Jurisson SS. Trithiols and their arsenic compounds for potential use in diagnostic and therapeutic radiopharmaceuticals. Nucl Med Biol 2016; 43:288-95. [PMID: 27150031 DOI: 10.1016/j.nucmedbio.2016.01.005] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2015] [Revised: 01/27/2016] [Accepted: 01/29/2016] [Indexed: 10/22/2022]
Abstract
INTRODUCTION Arsenic-72 ((72)As; 2.49MeV β(+), 26h) and (77)As (0.683MeV β(-), 38.8h) have nuclear properties useful for positron emission tomography (PET) and radiotherapy applications, respectively. Their half-lives are sufficiently long for targeting tumors with antibodies, as well as peptides. Potential radiopharmaceuticals based on radioarsenic require development of suitable bifunctional chelates for stable conjugation of arsenic to vectors under in vivo conditions at high dilution. METHODS The thiophilic nature of arsenic led to the synthesis and characterization of a simple trithiol ligand and its arsenic complex, and radiolabeling studies at the no carrier added (NCA) (77)As level. RESULTS (1)H- and (13)C-NMR spectroscopy, electrospray ionization mass spectrometry (ESI-MS), and single crystal X-ray diffraction were used to characterize the trithiol ligand and its arsenic(III) complex. Radiotracer studies with no carrier added (NCA) (77)As resulted in high radiolabeling yields (>96%) with high in vitro stability. CONCLUSIONS The high yield and stability of a single NCA (77)As trithiol complex indicates that this framework is suitable for developing matched pair agents for non-invasive in vivo PET imaging and radiotherapy of tumors with (72,77)As. This is the first reported chelate developed for NCA radioarsenic and studies are underway for developing a trithiol bifunctional chelate conjugated to a targeting vector, such as a peptide or monoclonal antibody.
Collapse
Affiliation(s)
| | - Yutian Feng
- Department of Chemistry, University of Missouri, Columbia, MO 65211, USA
| | - Charles L Barnes
- Department of Chemistry, University of Missouri, Columbia, MO 65211, USA
| | - Alan R Ketring
- Research Reactor Center (MURR), University of Missouri, Columbia, MO 65211, USA
| | - Cathy S Cutler
- Research Reactor Center (MURR), University of Missouri, Columbia, MO 65211, USA
| | - Silvia S Jurisson
- Department of Chemistry, University of Missouri, Columbia, MO 65211, USA; Research Reactor Center (MURR), University of Missouri, Columbia, MO 65211, USA.
| |
Collapse
|
42
|
Yuan A, Chai X, Martins F, Arai S, Arora M, Correa ME, Pidala J, Cutler CS, Lee SJ, Treister NS. Oral chronic GVHD outcomes and resource utilization: a subanalysis from the chronic GVHD consortium. Oral Dis 2015; 22:235-40. [PMID: 26708609 DOI: 10.1111/odi.12429] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2015] [Revised: 11/25/2015] [Accepted: 12/16/2015] [Indexed: 01/03/2023]
Abstract
OBJECTIVES This study evaluated the extent to which oral chronic graft-versus-host disease (cGVHD) consensus assessments are predictive of management across institutions with and without oral medicine (OM) centers, and whether ancillary care guidelines are followed within clinical practice. METHODS Longitudinal oral cGVHD data were abstracted from the cGVHD Consortium, and additional mouth-specific management data were analyzed across five transplant centers. RESULTS Seventy-nine patients with 656 visits were observed for a median of 7.1 months with one visit per follow-up month. Ancillary therapies for oral cGVHD were prescribed for 67% of patients for a median of 0.46 months (per follow-up month) at OM centers and 0.78 months at non-OM centers. Patients treated with ancillary therapy were more likely to have an National Institutes of Health (NIH) mouth score of ≥1 (P < 0.001, odds ratio: 5.1) and mouth pain (P = 0.01, odds ratio: 2.6). The odds ratios of receiving ancillary therapy from OM experts were higher than transplant physicians (53%; P = 0.03). CONCLUSIONS Oral cGVHD consensus assessments corresponding with ancillary therapy use were mouth pain and NIH mouth score, with higher odds ratios of receiving therapy from OM experts. Ancillary care guidelines for oral cGVHD are reflected in academic clinical practice with respect to utilization of recommended prescriptions.
Collapse
Affiliation(s)
- A Yuan
- Division of Oral Medicine, Brigham and Women's Hospital, Boston, MA, USA.,Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, MA, USA
| | - X Chai
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - F Martins
- Department of Oral Pathology and Oral Diagnosis, University of São Paulo School of Dentistry, São Paulo, Brazil
| | - S Arai
- Division of Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, CA, USA
| | - M Arora
- Department of Medicine, University of Minnesota, Boston, MA, USA
| | - M E Correa
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.,Oral Medicine Ambulatory, Bone Marrow Transplantation Unit, Hematology and Blood Transfusion Center, State University of Campinas (UNICAMP), Campinas, SP, Brazil
| | - J Pidala
- Department of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL, USA
| | - C S Cutler
- Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA
| | - S J Lee
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - N S Treister
- Division of Oral Medicine, Brigham and Women's Hospital, Boston, MA, USA.,Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, MA, USA
| |
Collapse
|
43
|
Cutler CS. Radiopharmacology: recent developments in the field of radiopharmaceuticals. Q J Nucl Med Mol Imaging 2015; 59:239-240. [PMID: 26404758] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Affiliation(s)
- C S Cutler
- Medical Isotope Research & Production Program, Collider-Accelerator Department, Brookhaven National Laboratory, Upton, NY, USA -
| |
Collapse
|
44
|
Aweda TA, Zhang S, Mupanomunda C, Burkemper J, Heo GS, Bandara N, Lin M, Cutler CS, Cannon CL, Youngs W, Wooley KL, Lapi SE. Investigating the pharmacokinetics and biological distribution of silver-loaded polyphosphoester-based nanoparticles using (111) Ag as a radiotracer. J Labelled Comp Radiopharm 2015; 58:234-41. [PMID: 25952472 PMCID: PMC4457551 DOI: 10.1002/jlcr.3289] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2015] [Accepted: 03/24/2015] [Indexed: 11/09/2022]
Abstract
Purified (111) Ag was used as a radiotracer to investigate silver loading and release, pharmacokinetics, and biodistribution of polyphosphoester-based degradable shell crosslinked knedel-like (SCK) nanoparticles as a comparison to the previously reported small molecule, N-heterocyclic silver carbene complex analog (SCC1) for the delivery of therapeutic silver ions in mouse models. Biodistribution studies were conducted by aerosol administration of (111) Ag acetate, [(111) Ag]SCC1, and [(111) Ag]SCK doses directly into the lungs of C57BL/6 mice. Nebulization of the (111) Ag antimicrobials resulted in an average uptake of 1.07 ± 0.12% of the total aerosolized dose given per mouse. The average dose taken into the lungs of mice was estimated to be 2.6 ± 0.3% of the dose inhaled per mouse for [(111) Ag]SCC1 and twice as much dose was observed for the [(111) Ag]SCKs (5.0 ± 0.3% and 5.9 ± 0.8% for [(111) Ag]aSCK and [(111) Ag]zSCK, respectively) at 1 h post administration (p.a.). [(111) Ag]SCKs also exhibited higher dose retention in the lungs; 62-68% for [(111) Ag]SCKs and 43% for [(111) Ag]SCC1 of the initial 1 h dose were observed in the lungs at 24 h p.a.. This study demonstrates the utility of (111) Ag as a useful tool for monitoring the pharmacokinetics of silver-loaded antimicrobials in vivo.
Collapse
Affiliation(s)
- Tolulope A. Aweda
- Mallinckrodt Institute of Radiology, Washington University School of Medicine in St. Louis, St. Louis, MO 63110
| | - Shiyi Zhang
- Department of Chemistry, Texas A&M University, College Station, TX 77843-3255
| | - Chiedza Mupanomunda
- Mallinckrodt Institute of Radiology, Washington University School of Medicine in St. Louis, St. Louis, MO 63110
| | - Jennifer Burkemper
- Mallinckrodt Institute of Radiology, Washington University School of Medicine in St. Louis, St. Louis, MO 63110
| | - Gyu Seong Heo
- Department of Chemistry, Texas A&M University, College Station, TX 77843-3255
| | - Nilantha Bandara
- Mallinckrodt Institute of Radiology, Washington University School of Medicine in St. Louis, St. Louis, MO 63110
| | - Mai Lin
- Mallinckrodt Institute of Radiology, Washington University School of Medicine in St. Louis, St. Louis, MO 63110
| | - Cathy S. Cutler
- University of Missouri, Research Reactor Center, 1513 Research Park Drive, Columbia, MO 65211
| | - Carolyn L. Cannon
- Department of Microbial Pathogenesis and Immunology, Texas A&M Health Science Center, 407 Reynolds Medical Building, College Station, TX 77843-1114
| | - Wiley Youngs
- Department of Chemistry, University of Akron, Akron, OH 44325-3601
| | - Karen L. Wooley
- Department of Chemistry, Texas A&M University, College Station, TX 77843-3255
| | - Suzanne E. Lapi
- Mallinckrodt Institute of Radiology, Washington University School of Medicine in St. Louis, St. Louis, MO 63110
| |
Collapse
|
45
|
Axiak-Bechtel SM, Upendran A, Lattimer JC, Kelsey J, Cutler CS, Selting KA, Bryan JN, Henry CJ, Boote E, Tate DJ, Bryan ME, Katti KV, Kannan R. Gum arabic-coated radioactive gold nanoparticles cause no short-term local or systemic toxicity in the clinically relevant canine model of prostate cancer. Int J Nanomedicine 2014; 9:5001-11. [PMID: 25378926 PMCID: PMC4218919 DOI: 10.2147/ijn.s67333] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Introduction Gum arabic-coated radioactive gold nanoparticles (GA-198AuNPs) offer several advantages over traditional brachytherapy in the treatment of prostate cancer, including homogenous dose distribution and higher dose-rate irradiation. Our objective was to determine the short-term safety profile of GA-198AuNPs injected intralesionally. We proposed that a single treatment of GA-198AuNPs would be safe with minimal-to-no evidence of systemic or local toxicity. Methods Nine dogs with spontaneously occurring prostatic cancer were treated. Injections were performed with ultrasound or computerized tomography guidance. Complete blood counts, chemistry panels, and urinalyses were performed at weekly intervals for 1 month and imaging was repeated 4 weeks postinjection. Planar scintigraphic images were obtained within 30 minutes of injection. Results No statistically significant difference was found in any hematologic or biochemical parameter studied, nor was any evidence of tumor swelling or abscessation found in eight dogs with repeat imaging; one dog died secondary to urethral obstruction 12 days following injection. At 30 minutes postinjection, an average of 53% of injected dose in seven dogs was retained in the prostate, with loss of remaining activity in the bladder and urethra; no systemic uptake was detected. Conclusion GA-198AuNP therapy had no short-term toxicity in the treatment of prostatic cancer. While therapeutic agent was found in the prostate immediately following injection, some loss of agent was detected in the bladder and urethra. Localization of radioactivity within the prostate was lower than anticipated and likely due to normal vestigial prostatic ducts. Therefore, further study of retention, dosimetry, long-term toxicity, and efficacy of this treatment is warranted prior to Phase I trials in men.
Collapse
Affiliation(s)
- Sandra M Axiak-Bechtel
- Department of Veterinary Medicine and Surgery, University of Missouri, Columbia, MO, USA
| | - Anandhi Upendran
- Department of Physics, University of Missouri, Columbia, MO, USA ; Nanoparticle Biochem, Inc., and Shasun-NBI LLC, Columbia, MO, USA
| | - Jimmy C Lattimer
- Department of Veterinary Medicine and Surgery, University of Missouri, Columbia, MO, USA
| | - James Kelsey
- Nanoparticle Biochem, Inc., and Shasun-NBI LLC, Columbia, MO, USA ; Missouri University Research Reactor, Columbia, MO, USA
| | | | - Kim A Selting
- Department of Veterinary Medicine and Surgery, University of Missouri, Columbia, MO, USA
| | - Jeffrey N Bryan
- Department of Veterinary Medicine and Surgery, University of Missouri, Columbia, MO, USA
| | - Carolyn J Henry
- Department of Veterinary Medicine and Surgery, University of Missouri, Columbia, MO, USA ; Department of Internal Medicine, University of Missouri, Columbia, MO, USA
| | | | - Deborah J Tate
- Department of Veterinary Medicine and Surgery, University of Missouri, Columbia, MO, USA
| | - Margaret E Bryan
- Department of Statistics, University of Missouri, Columbia, MO, USA
| | - Kattesh V Katti
- Nanoparticle Biochem, Inc., and Shasun-NBI LLC, Columbia, MO, USA ; Department of Radiology, University of Missouri, Columbia, MO, USA
| | - Raghuraman Kannan
- Nanoparticle Biochem, Inc., and Shasun-NBI LLC, Columbia, MO, USA ; Department of Radiology, University of Missouri, Columbia, MO, USA
| |
Collapse
|
46
|
Sakr T, Dorn HC, Zhang Z, Cutler CS. Evaluation of metallofullerens for potential use in therapy. Nucl Med Biol 2014. [DOI: 10.1016/j.nucmedbio.2014.05.130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
47
|
Black KCL, Wang Y, Luehmann HP, Cai X, Xing W, Pang B, Zhao Y, Cutler CS, Wang LV, Liu Y, Xia Y. Radioactive 198Au-doped nanostructures with different shapes for in vivo analyses of their biodistribution, tumor uptake, and intratumoral distribution. ACS Nano 2014; 8:4385-94. [PMID: 24766522 PMCID: PMC4358630 DOI: 10.1021/nn406258m] [Citation(s) in RCA: 241] [Impact Index Per Article: 24.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/03/2023]
Abstract
With Au nanocages as an example, we recently demonstrated that radioactive (198)Au could be incorporated into the crystal lattice of Au nanostructures for simple and reliable quantification of their in vivo biodistribution by measuring the γ radiation from (198)Au decay and for optical imaging by detecting the Cerenkov radiation. Here we extend the capability of this strategy to synthesize radioactive (198)Au nanostructures with a similar size but different shapes and then compare their biodistribution, tumor uptake, and intratumoral distribution using a murine EMT6 breast cancer model. Specifically, we investigated Au nanospheres, nanodisks, nanorods, and cubic nanocages. After PEGylation, an aqueous suspension of the radioactive Au nanostructures was injected into a tumor-bearing mouse intravenously, and their biodistribution was measured from the γ radiation while their tumor uptake was directly imaged using the Cerenkov radiation. Significantly higher tumor uptake was observed for the Au nanospheres and nanodisks relative to the Au nanorods and nanocages at 24 h postinjection. Furthermore, autoradiographic imaging was performed on thin slices of the tumor after excision to resolve the intratumoral distributions of the nanostructures. While both the Au nanospheres and nanodisks were only observed on the surfaces of the tumors, the Au nanorods and nanocages were distributed throughout the tumors.
Collapse
Affiliation(s)
- Kvar C. L. Black
- Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri 63110, United States
| | - Yucai Wang
- The Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, Georgia 30332, United States
| | - Hannah P. Luehmann
- Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri 63110, United States
| | - Xin Cai
- Department of Biomedical Engineering, Washington University, St. Louis, Missouri 63130, United States
| | - Wenxin Xing
- Department of Biomedical Engineering, Washington University, St. Louis, Missouri 63130, United States
| | - Bo Pang
- The Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, Georgia 30332, United States
| | - Yongfeng Zhao
- Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri 63110, United States
| | - Cathy S. Cutler
- University of Missouri Research Reactor, Columbia, Missouri 65211, United States
| | - Lihong V. Wang
- Department of Biomedical Engineering, Washington University, St. Louis, Missouri 63130, United States
| | - Yongjian Liu
- Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri 63110, United States
- Address correspondence to ,
| | - Younan Xia
- The Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, Georgia 30332, United States
- Address correspondence to ,
| |
Collapse
|
48
|
Cutler CS, Schwarz SW. Diversification in the Supply Chain of (99)Mo Ensures a Future for (99m)Tc. J Nucl Med 2014; 55:1208-13. [PMID: 24854794 DOI: 10.2967/jnumed.113.131953] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2013] [Accepted: 04/07/2014] [Indexed: 11/16/2022] Open
Abstract
The uncertain availability of (99m)Tc has become a concern for nuclear medicine departments across the globe. An issue for the United States is that currently it is dependent on a supply of (99m)Tc (from (99)Mo) that is derived solely by production outside the United States. Since the United States uses half the world's (99)Mo production, the U.S. (99)Mo supply chain would be greatly enhanced if a producer were located within the United States. The fragility of the old (99)Mo supply chain is being addressed as new facilities are constructed and new processes are developed to produce (99)Mo without highly enriched uranium. The conversion to low-enriched uranium is necessary to minimize the potential misuse of highly enriched uranium in the world for nonpeaceful means. New production facilities, new methods for the production of (99)Mo, and a new generator elution system for the supply of (99m)Tc are currently being pursued. The progress made in all these areas will be discussed, as they all highlight the need to embrace diversity to ensure that we have a robust and reliable supply of (99m)Tc in the future.
Collapse
Affiliation(s)
| | - Sally W Schwarz
- Department of Radiology, Washington University School of Medicine, St. Louis, Missouri
| |
Collapse
|
49
|
Wycoff DE, Gott MD, DeGraffenreid AJ, Morrow RP, Sisay N, Embree MF, Ballard B, Fassbender ME, Cutler CS, Ketring AR, Jurisson SS. Chromatographic separation of selenium and arsenic: A potential (72)Se/(72)As generator. J Chromatogr A 2014; 1340:109-14. [PMID: 24679827 PMCID: PMC4030290 DOI: 10.1016/j.chroma.2014.03.033] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2013] [Revised: 03/05/2014] [Accepted: 03/10/2014] [Indexed: 11/29/2022]
Abstract
An anion exchange method was developed to separate selenium and arsenic for potential utility in a (72)Se/(72)As generator. The separation of the daughter (72)As from the (72)Se parent is based on the relative acid-base behavior of the two oxo-anions in their highest oxidation states. At pH 1.5, selenate is retained on strongly basic anion exchange resin as HSeO4(-) and SeO4(2-), while neutral arsenic acid, H3AsO4, is eluted.
Collapse
Affiliation(s)
- Donald E Wycoff
- Department of Chemistry, University of Missouri, Columbia, MO 65211, United States
| | - Matthew D Gott
- Department of Chemistry, University of Missouri, Columbia, MO 65211, United States
| | | | - Ryan P Morrow
- Department of Chemistry, University of Missouri, Columbia, MO 65211, United States
| | - Nebiat Sisay
- Department of Chemistry, University of Missouri, Columbia, MO 65211, United States
| | - Mary F Embree
- University of Missouri Research Reactor Center, Columbia, MO 65211, United States
| | - Beau Ballard
- Chemistry Division, Los Alamos National Laboratory, Los Alamos, NM 87545, United States
| | - Michael E Fassbender
- Chemistry Division, Los Alamos National Laboratory, Los Alamos, NM 87545, United States
| | - Cathy S Cutler
- University of Missouri Research Reactor Center, Columbia, MO 65211, United States
| | - Alan R Ketring
- University of Missouri Research Reactor Center, Columbia, MO 65211, United States
| | - Silvia S Jurisson
- Department of Chemistry, University of Missouri, Columbia, MO 65211, United States.
| |
Collapse
|
50
|
Thompson S, Ballard B, Jiang Z, Revskaya E, Sisay N, Miller WH, Cutler CS, Dadachova E, Francesconi LC. 166Ho and 90Y labeled 6D2 monoclonal antibody for targeted radiotherapy of melanoma: comparison with 188Re radiolabel. Nucl Med Biol 2014; 41:276-81. [PMID: 24533987 PMCID: PMC5437724 DOI: 10.1016/j.nucmedbio.2013.12.015] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2013] [Revised: 12/13/2013] [Accepted: 12/19/2013] [Indexed: 10/25/2022]
Abstract
INTRODUCTION An approach to radioimmunotherapy (RIT) of metastatic melanoma is the targeting of melanin pigment with monoclonal antibodies (mAbs) to melanin radiolabeled with therapeutic radionuclides. The proof of principle experiments were performed using a melanin-binding antibody 6D2 of IgM isotype radiolabeled with a β emitter (188)Re and demonstrated the inhibition of tumor growth. In this study we investigated the efficacy of 6D2 antibody radiolabeled with two other longer lived β emitters (90)Y and (166)Ho in treatment of experimental melanoma, with the objective to find a possible correlation between the efficacy and half-life of the radioisotopes which possess high energy β (E(max)>1.5 MeV) emission properties. METHODS 6D2 was radiolabeled with longer lived β emitters (90)Y and (166)Ho in treatment of experimental melanoma in A2058 melanoma tumor-bearing nude mice. The immunoreactivity of the radiolabeled 6D2 mAb, its in vitro binding to the MNT1 human melanoma cells, the biodistribution and therapy in A2058 human melanoma bearing nude mice as well as dosimetry calculations were performed. RESULTS When labeled with the longer lived (90)Y radionuclide, the 6D2 mAb did not produce any therapeutic effect in tumor bearing mice while the reduction of the tumor growth by (166)Ho-6D2 was very similar to the previously reported therapy results for (188)Re-6D2. In addition, (166)Ho-labeled mAb produced the therapeutic effect on the tumor without any toxic effects while the administration of the (90)Y-labeled radioconjugate was toxic to mice with no appreciable anti-tumor effect. CONCLUSIONS (166)Ho-labeled mAb to melanin produced some therapeutic effect on the tumor without any toxic effects while the administration of the (90)Y-labeled radioconjugate was toxic to mice with no appreciable anti-tumor effect. We concluded that the serum half-life of the 6D2 carrier antibody matched well the physical half-life of (166)Ho to deliver the tumoricidal absorbed dose to the tumor. Further investigation of this radionuclide for RIT of melanoma is warranted.
Collapse
Affiliation(s)
- S Thompson
- Department of Chemistry, Hunter College of the City University of New York, 695 Park Avenue, New York, NY 10065, USA.
| | - B Ballard
- Department of Chemistry, Hunter College of the City University of New York, 695 Park Avenue, New York, NY 10065, USA
| | - Z Jiang
- Albert Einstein College of Medicine, Bronx, NY, USA
| | - E Revskaya
- Albert Einstein College of Medicine, Bronx, NY, USA
| | - N Sisay
- Missouri University Research Reactor, Columbia, MO, 65211 USA
| | - W H Miller
- Missouri University Research Reactor, Columbia, MO, 65211 USA
| | - C S Cutler
- Missouri University Research Reactor, Columbia, MO, 65211 USA
| | - E Dadachova
- Albert Einstein College of Medicine, Bronx, NY, USA
| | - L C Francesconi
- Department of Chemistry, Hunter College of the City University of New York, 695 Park Avenue, New York, NY 10065, USA
| |
Collapse
|